Tokyo Tape
Sign in
← PeptiDream

Half-year report · Q2

4587.TEDINET S100WHGM
Period2025-01-01 → 2025-06-30
Filed2025-08-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥8.5bn2025-01-01 → 2025-06-30Cons.Revenue IFRS
Revenue¥46.7bn2024-01-01 → 2024-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥36.1bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Operating income−¥2.6bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Operating income¥24.6bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Profit before tax−¥2.9bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Profit before tax¥20.9bn2024-01-01 → 2024-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥24.7bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Net income (owners)−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.0bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Net income¥15.0bn2024-01-01 → 2024-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Total assets¥78.5bnat 2025-06-30Cons.Assets IFRS
Total assets¥92.8bnat 2024-12-31Cons.Assets IFRS
Total assets¥95.9bnat 2024-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥24.9bnat 2025-06-30Cons.Liabilities IFRS
Total liabilities¥36.0bnat 2024-12-31Cons.Liabilities IFRS
Net assets / equity¥53.7bnat 2025-06-30Cons.Equity IFRS
Net assets / equity¥56.8bnat 2024-12-31Cons.Equity IFRS
Net assets / equity¥58.8bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31vCons.Equity IFRS
Equity (owners)¥53.7bnat 2025-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥56.8bnat 2024-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥58.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥33.3bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥48.1bnat 2024-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥25.5bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow−¥11.0bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥23.8bn2024-01-01 → 2024-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥2.7bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.3bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥8.4bn2024-01-01 → 2024-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥10.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.5bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥3.0bn2024-01-01 → 2024-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-16.42025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥115.852024-01-01 → 2024-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥138.32024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-16.42025-01-01 → 2025-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥115.682024-01-01 → 2024-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥138.112024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio68.3%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.2%at 2024-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.3%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥453m
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥453m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥761m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥761m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥3.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥8.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥453m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2025-01-01 → 2025-06-30¥436m
—segment totalrevenue2025-01-01 → 2025-06-30¥9.0bn
—segment totalrevenue external2025-01-01 → 2025-06-30¥8.5bn
—segment totalrevenue intersegment2025-01-01 → 2025-06-30¥453m
—segment totalsegment profit2025-01-01 → 2025-06-30−¥2.6bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥178m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥178m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-06-30¥24.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥7.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥178m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥47m
—segment totalrevenue2024-01-01 → 2024-06-30¥36.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥36.1bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥178m
—segment totalsegment profit2024-01-01 → 2024-06-30¥24.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 582
ItemContextValueUnit
Comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember18394750000JPY
Comprehensive income IFRSPrior1YTDDuration18394750000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember-143000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-143000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration-143000JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember10562000JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember10562000JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration10562000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember6539253000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember-6539253000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember15756000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember15756000JPY
Share based payment transactions ss IFRSPrior1YTDDuration15756000JPY
Total transactions with owners IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Total transactions with owners IFRSPrior1YTDDuration_CapitalSurplusIFRSMember15756000JPY
Total transactions with owners IFRSPrior1YTDDuration_TreasurySharesIFRSMember10418000JPY
Total transactions with owners IFRSPrior1YTDDuration_RetainedEarningsIFRSMember6539253000JPY
Total transactions with owners IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember-6539253000JPY
Total transactions with owners IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember26174000JPY
Total transactions with owners IFRSPrior1YTDDuration26174000JPY
Equity IFRSPrior1QuarterInstant_ShareCapitalIFRSMember3956738000JPY
Equity IFRSPrior1QuarterInstant_CapitalSurplusIFRSMember4566129000JPY
Equity IFRSPrior1QuarterInstant_TreasurySharesIFRSMember-1075128000JPY
Equity IFRSPrior1QuarterInstant_RetainedEarningsIFRSMember52269245000JPY
Equity IFRSPrior1QuarterInstant_OtherComponentsOfEquityIFRSMember-946349000JPY
Equity IFRSPrior1QuarterInstant_EquityAttributableToOwnersOfParentIFRSMember58770634000JPY
Equity IFRSPrior1QuarterInstant58770634000JPY
Equity IFRSPrior1YearInstant_ShareCapitalIFRSMember3956738000JPY
Equity IFRSPrior1YearInstant_CapitalSurplusIFRSMember4736195000JPY
Equity IFRSPrior1YearInstant_TreasurySharesIFRSMember-1075148000JPY
Equity IFRSPrior1YearInstant_RetainedEarningsIFRSMember49393469000JPY
Equity IFRSPrior1YearInstant_OtherComponentsOfEquityIFRSMember-248956000JPY
Equity IFRSPrior1YearInstant_EquityAttributableToOwnersOfParentIFRSMember56762298000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass